Kexiang Xi1, Hui Yu2,3, Kexing Xi4. 1. Department of Obstetrics, Jieyang People's Hospital, Jieyang, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 3. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. 4. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Abstract
BACKGROUND: There is no consensus on the optimal number of examined LNs for stage IV rectal cancer patients after preoperative therapy. We aimed to explore the impact of the number of resected lymph nodes (LNs) on the survival outcomes of stage IV rectal cancer patients after preoperative therapy. METHODS: Clinicopathologic data of 556 patients diagnosed with stage IV rectal cancer between 1st January, 2010 and 31st December, 2015 from the Surveillance, Epidemiology, and End Results (SEER) database after preoperative therapy were reviewed. The patients were further divided into two groups: the ≥15 resected LNs group and <15 resected LNs group based on the X-tile software analysis results of the number of resected LNs. RESULTS: Both univariate and multivariate regression analyses revealed that the number of resected LNs and N status were significantly positively correlated with the survival outcome of the patients. Patients in the ≥15 resected LNs group had a significant better cancer-specific survival (CSS) (P=0.003) than those in the <15 resected LNs group. The 3-year CSS rate was 63.2% for patients with ≥15 resected LNs compared with 55.7% for those with <15 resected LNs. The 5-year CSS rate was 50.2% and 30.5% for patients in the ≥15 resected LNs group and those in the <15 resected LNs group, respectively. CONCLUSIONS: The number of resected LNs is an important independent prognostic factor that influences the survival outcome of stage IV rectal cancer patients after receiving preoperative therapy. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: There is no consensus on the optimal number of examined LNs for stage IV rectal cancer patients after preoperative therapy. We aimed to explore the impact of the number of resected lymph nodes (LNs) on the survival outcomes of stage IV rectal cancer patients after preoperative therapy. METHODS: Clinicopathologic data of 556 patients diagnosed with stage IV rectal cancer between 1st January, 2010 and 31st December, 2015 from the Surveillance, Epidemiology, and End Results (SEER) database after preoperative therapy were reviewed. The patients were further divided into two groups: the ≥15 resected LNs group and <15 resected LNs group based on the X-tile software analysis results of the number of resected LNs. RESULTS: Both univariate and multivariate regression analyses revealed that the number of resected LNs and N status were significantly positively correlated with the survival outcome of the patients. Patients in the ≥15 resected LNs group had a significant better cancer-specific survival (CSS) (P=0.003) than those in the <15 resected LNs group. The 3-year CSS rate was 63.2% for patients with ≥15 resected LNs compared with 55.7% for those with <15 resected LNs. The 5-year CSS rate was 50.2% and 30.5% for patients in the ≥15 resected LNs group and those in the <15 resected LNs group, respectively. CONCLUSIONS: The number of resected LNs is an important independent prognostic factor that influences the survival outcome of stage IV rectal cancer patients after receiving preoperative therapy. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Rectal cancer; Survival, Surveillance, Epidemiology, and End Results database (SEER database); number of resected lymph nodes; stage IV
Authors: Coen L Klos; Paul C Shellito; David W Rattner; Richard A Hodin; James C Cusack; Liliana Bordeianou; Patricia Sylla; Theodore S Hong; Lawrence Blaszkowsky; Davis P Ryan; Gregory Y Lauwers; Yuchiao Chang; David L Berger Journal: Am J Surg Date: 2010-10 Impact factor: 2.565
Authors: Dietrich Doll; Ralf Gertler; Matthias Maak; Jan Friederichs; Karen Becker; Hans Geinitz; Monika Kriner; Hjalmar Nekarda; Jörg R Siewert; Robert Rosenberg Journal: World J Surg Date: 2009-02 Impact factor: 3.352
Authors: Daniel C Damin; Mário A Rosito; Paulo C Contu; Cláudio Tarta; Paulo R Ferreira; Lucia M Kliemann; Gilberto Schwartsmann Journal: J Gastrointest Surg Date: 2012-05-23 Impact factor: 3.452
Authors: Marco La Torre; Laura Lorenzon; Emanuela Pilozzi; Viola Barucca; Marco Cavallini; Vincenzo Ziparo; Mario Ferri Journal: J Surg Oncol Date: 2012-03-27 Impact factor: 3.454
Authors: Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Lisa Gurski; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2018-07 Impact factor: 11.908